DNLI

Neutral

Denali Therapeutics (NASDAQ:DNLI) Stock Rating Lowered by Wall Street Zen

Wall Street Zen downgraded Denali Therapeutics (NASDAQ:DNLI) from a "sell" to a "strong sell" rating. Despite this, the consensus among analysts remai...

MarketBeat 2 weeks ago 0

Neutral

Denali CEO’s ‘greatest professional moment’ arrives as rare disease drug launches

Denali Therapeutics CEO Ryan Watts describes the FDA approval of Avlayah, a Hunter syndrome drug, as the "greatest professional moment" of his life, c...

BioSpace 3 weeks ago 0